Publications
NeOnc Technologies continues to publish the results of its ongoing studies on the efficacy and applications of our products. Below are links to these publications.
NEO 100
The base formulation for all NeOnc Technologies products. NEO 100 is a highly purified form of the natural compound Perillyl Alcohol (POH).
NEO 212
NEO 212 is a chemical conjugation of the DNA alkylating agent Temozolomide (TMZ) with our highly purified formulation of Perillyl Alcohol (POH). TMZ continues to be the gold standard in the treatment of anaplastic astrocytoma, and glioblastoma multiforme cancers.
NEO 214
NEO 214 is a chemical conjugation of the phosphodiesterase type IV inhibitor Rolipram with our highly purified formulation of Perillyl Alcohol (POH). Rolipram has several corollary effects that make it a promising candidate in the treatment of many neurodegenerative diseases including Alzheimer’s
NEO 218
NEO 218 is a conjugate formulation of 3-Bromopyruvate (3BP) and our highly refined Perillyl Alcohol (POH). 3BP is a small, highly reactive molecule noted for its high efficacy for anticancer therapy, especially for its antitumor properties.
NEO 412
NEO 412 was created to build on the therapeutic effect of its NEO 400 formulation. to target the treatment of melanoma and basal skin cancers by adding Temozolomide (TMZ) to the formulation.